Acrongenomics Inc. Appoints De Facto Communications to Provide Public & Investor Relations Services

Jan. 4, 2008 - PRLog -- Acrongenomics Inc.  announces today that it has appointed London based De Facto Communications to manage its public and investor relations from January 2008. De Facto’s appointment is a key part of the strategy to finalise the development and commercialisation of the point-of-care diagnostic device that the Company is in the process of fully acquiring. De Facto’s role will be to continue to build the reputation of Acrongenomics with all stakeholders in Europe and North America as the Company completes its acquisition of Molecular Vision Limited and moves towards earning its first revenues.

In November 2007, Acrongenomics Inc. announced that they had signed a letter of intent for the acquisition of 100% of Molecular Vision Limited, (“Molecular Vision”) a private U.K. company that specializes in the development of miniaturized Point-of-Care (POC) medical diagnostic devices. Molecular Vision was set up in 2002 by Professor Donal Bradley, Professor Andrew De Mello and Dr. John De Mello at Imperial College in the UK to converge technology in fluidics with technology in light emitting polymers to produce a patented diagnostic detection system that would be truly portable and well placed to exploit the growing demand for reliable and rapid diagnosis at the point of treatment. Under the terms of the Letter of Intent, the three academic founders, and their team will be part of Acrongenomics and continue to lead the development of the POC devices and technology at the merged company.

Acrongenomics has been working closely with Molecular Vision for some while now and previously entered into a Joint Development Agreement with the Company in May 2006 to acquire the exclusive rights to develop and commercialize existing intellectual properties relating to Molecular Visions’ patented “BioLED” Technology including the fields of Kidney, Cardiovascular, Sexually Transmitted Diseases, and Drugs of Abuse biomarkers. The tremendous progress achieved by the team since the collaboration started, recently demonstrated by the detection of creatinine in urine using the POC device, let Acrongenomics move forward to acquire 100% of Molecular Vision.


Dr. Dimitri Goudis, CEO of Acrongenomics, Inc., commenting on the appointment of DeFacto said; “Following the very successful demonstration of the pilot system at Imperial College in October 2007, it was clear that Acrongenomics should commit itself to provide sufficient financing to make the Molecular Vision dream a reality. Finding the appropriate team to support us as we commercialise this exciting technology has been very important to us and we are delighted to be able to appoint the De Facto team.”

About Acrongenomics Inc.

Acrongenomics Inc. is a publicly traded company that focuses on investing in and commercializing novel technology platforms concerning the Life Sciences sector. Acrongenomics brings novel and realistic concepts to market by transforming scientific innovations into tangible, consumer-orientated applications.

About De Facto Communications

De Facto Communications is one of Europe's most successful public relations consultancies in life science, healthcare and clinical trials marketing. In partnership with our clients, we approach our work with a passion and commitment that delivers award-winning, integrated communications programs based on effective strategy, original thinking and creativity. De Facto is headquartered in London and operates internationally with clients across Europe and the US. Further information on De Facto Communications can be found at http://www.defacto.com

Important Information About Forward-Looking Statements

All statements in this news release that are other than statements of historical facts are forward-looking statements which contain our current expectations about our future results. Forward-looking statements involve numerous risks and uncertainties. We have attempted to identify any forward-looking statements by using words such as "anticipates", "believes", "could", "expects", "intends", "may", "should" and other similar expressions. Although we believe that the expectations reflected in all of our forward looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. A number of factors may affect our future results and may cause those results to differ materially from those indicated in any forward-looking statements made by us or on our behalf. Such factors include our limited operating history; our need for significant capital to finance internal growth as well as strategic acquisitions; our ability to attract and retain key employees and strategic partners; our ability to achieve and maintain profitability; fluctuations in the trading price and volume of our stock; competition from other providers of similar products and services; and other unanticipated future events and conditions. For further information concerning risks and uncertainties that may affect our future results, please review the disclosures contained in our latest filings with the SEC, including our most recent annual report on Form 10-KSB, and subsequent quarterly reports on Form 10-QSB. Other than as required by federal securities laws, we undertake no obligation to publicly update or revise any of our forward-looking statements, whether as a result of changed circumstances, new information, future events, or for any other reason occurring after the date of this news release.

Website: www.acrongen.com